Analytical Data
-
Gene name
CDK1
- Application
-
Alternative Names
CDK1；CDC2；CDC28A；CDKN1；Cyclin-dependent kinase 1
-
Species
Human
-
Source
E. coli
-
Tag
N-GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P06493
-
Expression Region
1-297aa
-
AA Sequence
MEDYTKIEKIGEGTYGVVYKGRHKTTGQVVAMKKIRLESEEEGVPSTAIREISLLKELRHPNIVSLQDVLMQDSRLYLIFEFLSMDLKKYLDSIPPGQYMDSSLVKSYLYQILQGIVFCHSRRVLHRDLKPQNLLIDDKGTIKLADFGLARAFGIPIRVYTHEVVTLWYRSPEVLLGSARYSTPVDIWSIGTIFAELATKKPLFHGDSEIDQLFRIFRALGTPNNEVWPEVESLQDYKNTFPKWKPGSLASHVKNLDENGLDLLSKMLIYDPAKRISGKMALNHPYFNDLDNQIKKM
-
Molecular Weight
60 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Identification
Protein Description
CDK1, or Cyclin-Dependent Kinase 1, is a crucial regulator of the cell cycle, primarily involved in orchestrating the transition from the G2 phase to mitosis. This serine/threonine kinase, when activated by its associated cyclin, plays a significant role in controlling cell division by phosphorylating various substrates that are essential for mitotic processes. Dysregulation of CDK1 activity has been implicated in various cancers, making it a potential target for therapeutic intervention. The study of CDK1 recombinant protein involves the expression and purification of CDK1 in heterologous systems, which allows for in-depth functional analyses, structure-function studies, and screening of small molecule inhibitors. Understanding the dynamics of CDK1 through recombinant techniques can provide insights into its mechanistic roles in cell cycle regulation, contribute to the identification of novel drug candidates, and help elucidate the molecular underpinnings of CDK1-related pathologies. Moreover, the development of specific inhibitors against CDK1 can pave the way for targeted cancer therapies, offering a promising approach to overcome the limitations of conventional treatments. Thus, research on CDK1 recombinant protein is pivotal in advancing our knowledge in cell biology and developing innovative strategies to combat cancer.
